Claim Missing Document
Check
Articles

Found 2 Documents
Search

Nasopharyngeal Non Hodgkin Lymphoma Wardhani, Shinta Oktya; Kartikasari, Nanik Triana
Jurnal Kedokteran Brawijaya Vol 29, No. 3 (2017)
Publisher : Fakultas Kedokteran Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jkb.2017.029.03.15

Abstract

Non Hodgkin lymphomas (NHL) are tumors originating from lymphoid tissue, mainly from lymph nodes. These tumors may result from chromosomal translocation, infections, environmental factors, immunodeficiency states, and chronic inflammation. In general, the incidence of NHL is slightly higher in men than in women. The incidence of NHL nasopharynx is rare. A high degree of suspicion is required to avoid unnecessary radiologic and surgical procedures since NHL can be mistakenly diagnosed as carcinoma. We reported a 16 year old male patient with gradual epistaxis, hearing impairment, decreased body weight, and multiple nodules in right forehead, right axilla, right colli posterior, and left waist. The patient also suffered from inferior paraplegic extremities. The Head CT scan result showed carcinoma nasopharynx. After biopsy of nodules was done, it revealed differential diagnoses such as blastoma, Non Hodgkin lymphoma, and small cell carcinoma. Immunohistochemistry result showed Leucocyte Common Antigen (LCA) positive, and MRI thorax showed suspect of schwannoma. Based on the data, chemotherapy with regiment CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin/vincristine, and prednisone) was given. The prognosis of NHL Nasopharynx was better than nasopharyngeal squamous cell carcinoma. The prognostic of NHL depends on the age, performance status, staging, extranodal involvement, serum Lactate Dehydrogenase (LDH) and response of therapy. The prognosis in our patient was poor.Keywords: Mass, Non Hodgkin Lymphoma, nasopharyngeal carcinoma, prognostic
Expression of Testicular Estrogen Receptor Alpha in Rats Exposed to Subchronic Inhalation Exposure of Transfluthrin Kartikasari, Nanik Triana; Arsana, Putu Moda; Soeatmadji, Djoko Wahono
Clinical and Research Journal in Internal Medicine Vol 1, No 1 (2020): New: The First Volume of Clinical and Research Journal in Internal Medicine
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.crjim.2020.001.01.3

Abstract

Endocrine Disrupting compounds (EDCs) are exogenous materials that can interfere with the functions of the endocrine system. Research has demonstrated that pyrethroid compounds affect endocrine function. Transfluthrin belongs to the pyrethroid group that is widely used. These compounds could interact with estrogen receptor α and may increase the expression of estrogen receptor α in rat testis. Aim: to determine the effect of subchronic inhaled transfluthrin exposure on the expression of estrogen receptor α (ERα). Method: we used 35 adult male Wistar rats as experimental animals, which were randomly divided into 5 groups (n=7 per group): negative control group (rats without treatment), solvent control group (rats exposed to n-hexane solvent), and three treatment groups of subchronic inhaled transfluthrin: 0.1 mg/ml (treatment 1),  0.2 mg/ml (treatment 2) and 0.4 mg/ml (treatment 3), treated for 60 days. The immunohistochemical (IHC) staining was used to assess the expression of ERα. Result: there was a tendency for an increase in ERα expression with the addition of a transfluthrin dose. ER α in negative control group, solvent control group, treatment 1 group, treatment 2 group, and treatment 3 group was 16.75 ± 5.01 %; 16.64 ± 13.00 %; 19.31 ± 6.52 %; 25.63 ± 7.08 %, and 28.79 ± 20.31 %; p>0.05, respectively. There was a weak positive correlation between the dose of transfluthrin with ERα expression (r = 0.38, p = 0.025). Conclusion: subchronic inhalation exposure of transfluthrin in rats showed a tendency to increased the expression of ERα (dose-dependent). There is a weak positive correlation between the dose of transfluthrin with ERα expression.                                                                                           Â